Regulation of ErbB2 receptor status by the proteasomal DUB POH1

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Liu, Han ^a   Buus, Richard ^a   Clague, Michael J ^a   Urbé, Sylvie ^a  

^a MRC Centre for Drug Safety Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; DEUBIQUITINATING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOXOMICIN; PROTEASOME; PROTEIN POH1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PSMD14 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; UBIQUITIN;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; CATALYSIS; CELL CULTURE; FLOW CYTOMETRY; GENETICS; METABOLISM;

CATALYSIS; CELLS, CULTURED; DOWN-REGULATION; FLOW CYTOMETRY; HELA CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; UBIQUITIN;

EID: 65849488473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005544     Document Type: Article

References (33)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
2. Sorkin A, Goh LK (2008) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 314: 3093-3106.
3. Urbe S (2005) Ubiquitin and endocytic protein sorting. Essays Biochem 41: 81-98.
4. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, et al. (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. Embo J 17: 3385-3397.
5. Wang Z, Zhang L, Yeung TK, Chen X (1999) Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 10: 1621-1636.
6. Haslekas C, Breen K, Pedersen KW, Johannessen LE, Stang E, et al. (2005) The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell 16: 5832-5842.
7. Worthylake R, Opresko LK, Wiley HS (1999) ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865-8874.
8. Finley D, Ciechanover A, Varshavsky A (2004) Ubiquitin as a central cellular regulator. Cell 116: S29-32, 22 p following S32.
9. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801.
10. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, et al. (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278: 13829-13837.
11. Citri A, Alroy I, Lavi S, Rubin C, Xu W, et al. (2002) Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. Embo J 21: 2407-2417.
12. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, et al. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282.
13. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 119: 85-95.
14. Pedersen NM, Madshus IH, Haslekas C, Stang E (2008) Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res 6: 491-500.
15. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, et al. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786.
16. Daviet L, Colland F (2008) Targeting ubiquitin specific proteases for drug discovery. Biochimie 90: 270-283.
17. Yang S, Raymond-Stintz MA, Ying W, Zhang J, Lidke DS, et al. (2007) Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J Cell Sci 120: 2763-2773.
18. Berkers JA, van Bergen en Henegouwen PM, Boonstra J (1991) Three classes of epidermal growth factor receptors on HeLa cells. J Biol Chem 266: 922-927.
19. Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, et al. (2002) A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416: 451-455.
20. Koulich E, Li X, Demartino GN (2008) Relative Structural and Functional Roles of Multiple Deubiquitylating Proteins Associated with Mammalian 26S Proteasome. Mol Biol Cell 19: 1072-1082.
21. McCullough J, Clague MJ, Urbe S (2004) AMSH is an endosome-associated ubiquitin isopeptidase. J Cell Biol 166: 487-492.
22. Clague MJ, Urbe S (2006) Endocytosis: the DUB version. Trends Cell Biol 16: 551-559.
23. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, et al. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 99: 12847-12852.
24. Verma R, Aravind L, Oania R, McDonald WH, Yates JR 3rd, et al. (2002) Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298: 611-615.
25. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, et al. (2003) Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278: 21323-21326.
26. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, et al. (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5: 461-466.
27. Shen F, Lin Q, Childress C, Yang W (2008) Identification of the domain in ErbB2 that restricts ligand-induced degradation. Cell Signal 20: 779-786.
28. Geetha T, Wooten MW (2008) TrkA receptor endolysosomal degradation is both ubiquitin and proteasome dependent. Traffic 9: 1146-1156.
29. Alwan HA, van Leeuwen JE (2007) UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. J Biol Chem 282: 1658-1669.
30. Marx C, Yau C, Banwait S, Zhou Y, Scott GK, et al. (2007) Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol 71: 1525-1534.
31. Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, et al. (2006) Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 5: 3042-3051.
32. Urbé S, Mills IG, Stenmark H, Kitamura N, Clague MJ (2000) Endosomal localization and receptor dynamics determine tyrosine phosphorylation of hepatocyte growth factor-regulated tyrosine kinase substrate. Mol Cell Biol 20: 7685-7692.
33. Row PE, Clague MJ, Urbe S (2005) Growth factors induce differential phosphorylation profiles of the Hrs-Stam complex: a common node in signaling networks with signal specific properties. Biochem J 389: 629-636.